

# EDWARDS LIFESCIENCES CORP

ISIN: US28176E1082 WKN: 28176E108 Asset Class: **Stock**

## Company

2024/04/26 22:00:02



Edwards

Price

**86.43**

USD

Difference

**-1.80% (-1.58)**



## Contact Details

EDWARDS  
LIFESCIENCES CORP.

Tel: +1-949-250-2500

--

Fax: +

1 Edwards Way

Web: <http://www.edwards.com>

92614 Irvine

E-mail:  
[customerservice\\_us@edwards.com](mailto:customerservice_us@edwards.com)

## Company Profile

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023          |                        | 2022          |                        | 2021          |                        |
|---------------------------------------|---------------|------------------------|---------------|------------------------|---------------|------------------------|
|                                       | Assets        | Liabilities and equity | Assets        | Liabilities and equity | Assets        | Liabilities and equity |
| <b>Current assets</b>                 | 4,035,700,000 |                        | 3,095,800,000 |                        | 3,180,700,000 |                        |
| <b>Common stock capital</b>           |               | 650,500,000            |               | 646,300,000            |               | 642,000,000            |
| <b>Fixed assets</b>                   | 5,327,500,000 |                        | 5,196,700,000 |                        | 5,321,900,000 |                        |
| <b>Equity capital of a company</b>    |               | 6,719,400,000          |               | 5,806,700,000          |               | 5,835,900,000          |
| <b>Cash and cash equivalents</b>      | 1,147,300,000 |                        | 769,500,000   |                        | 864,300,000   |                        |
| <b>Accrued liabilities</b>            |               | 433,500,000            |               | 410,500,000            |               | 450,300,000            |
| <b>Other assets</b>                   | -             |                        | -             |                        | -             |                        |
| <b>Current liabilities</b>            |               | 1,195,400,000          |               | 1,022,400,000          |               | 1,032,300,000          |
| <b>Prepayments and accrued income</b> | -             |                        | -             |                        | -             |                        |
| <b>Non-current liabilities</b>        |               | 1,448,400,000          |               | 1,463,400,000          |               | 1,634,400,000          |
| <b>Different income</b>               |               | -                      |               | -                      |               | -                      |
| <b>Other liabilities</b>              |               | 344,900,000            |               | 387,100,000            |               | 519,300,000            |
| <b>Total assets</b>                   | 9,363,200,000 | 9,363,200,000          | 8,292,500,000 | 8,292,500,000          | 8,502,600,000 | 8,502,600,000          |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 19,800  | 17,300  | 15,700  |
| <b>Equity ratio</b>        | 72.51%  | 70.02%  | 68.64%  |
| <b>Debt-equity ratio</b>   | 37.92%  | 42.81%  | 45.69%  |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 12.43% | 13.89% | 11.69% |

# EDWARDS LIFESCIENCES CORP

ISIN: US28176E1082 WKN: 28176E108 Asset Class: **Stock**

## Income statement

|  | 2023          | 2022          | 2021          |
|--|---------------|---------------|---------------|
| <b>Turnover</b>  | 6,004,800,000 | 5,382,400,000 | 5,232,500,000 |
| <b>Net income</b>  | 1,402,400,000 | 1,521,900,000 | 1,503,100,000 |
| <b>EBIT</b>  | 1,453,676,840 | 1,643,120,260 | 1,597,605,240 |
| <b>Operating income before taxes</b>                                 | 1,598,100,000 | 1,767,400,000 | 1,702,000,000 |
| <b>Cash Flow</b>   | 895,800,000   | 1,218,200,000 | 1,732,100,000 |
| <b>Net interest income</b>   | 42,700,000    | 9,300,000     | -7,400,000    |
| <b>Research and development expenses</b>                             | 1,071,800,000 | 945,200,000   | 903,100,000   |
| <b>Income taxes</b>  | 198,700,000   | 245,500,000   | 198,900,000   |
| <b>Result from investments in subsidiaries, associates and other</b> | -             | -             | -             |
| <b>Revenues per employee</b>   | 283,439       | 290,774       | 311,484       |

## Board of Directors

## Members of Management Board

|                       |                                |
|-----------------------|--------------------------------|
| Michael Mussallem     | Chairman of Board of Directors |
| Nicholas Valeriani    | Member of Board of Directors   |
| Kieran Gallahue       | Member of Board of Directors   |
| Leslie Heisz          | Member of Board of Directors   |
| Martha Marsh          | Member of Board of Directors   |
| Paul LaViolette       | Member of Board of Directors   |
| Ramona Sequeira       | Member of Board of Directors   |
| Steven Loranger       | Member of Board of Directors   |
| Arnold A. Pinkston    | Member of Executive Committee  |
| Bernard J. Zovighian  | Member of Executive Committee  |
| Catherine M. Szyman   | Member of Executive Committee  |
| Christine Z. McCauley | Member of Executive Committee  |
| Daveen Chopra         | Member of Executive Committee  |
| Dirksen J. Lehman     | Member of Executive Committee  |
| Donald E. Bobo, Jr.   | Member of Executive Committee  |
| Gary I. Sorsher       | Member of Executive Committee  |
| Jean-Luc Lemercier    | Member of Executive Committee  |
| Joseph Nuzzolese      | Member of Executive Committee  |
| Larry L. Wood         | Member of Executive Committee  |
| Scott B. Ullem        | Member of Executive Committee  |
| Todd J. Brinton       | Member of Executive Committee  |
| Wayne Markowitz       | Member of Executive Committee  |